Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
October 17, 2023
Assignee:
XOMA (US) LLC
Inventors:
Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
June 27, 2023
Assignees:
XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Abstract: The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered nifedipine in combination with a prostaglandin F2? (PGF2?) antagonist. Exemplary PGF2? receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride.
Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
August 24, 2021
Assignee:
XOMA TECHNOLOGY LTD.
Inventors:
Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
June 15, 2021
Assignees:
Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.
Inventors:
Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
Abstract: Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
Type:
Application
Filed:
February 24, 2020
Publication date:
January 14, 2021
Applicant:
XOMA (US) LLC
Inventors:
Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
December 8, 2020
Assignees:
XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Inventors:
Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
Type:
Grant
Filed:
March 3, 2016
Date of Patent:
July 14, 2020
Assignee:
XOMA (US) LLC
Inventors:
Kirk W. Johnson, Rajneesh Nath, Paul Rubin
Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
June 16, 2020
Assignees:
XOMA Technology Ltd., The Regents of the University of California
Inventors:
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
April 7, 2020
Assignee:
XOMA (US) LLC
Inventors:
Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
Type:
Grant
Filed:
August 1, 2017
Date of Patent:
December 31, 2019
Assignee:
XOMA (US) LLC
Inventors:
Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
July 23, 2019
Assignee:
XOMA Technology, Ltd.
Inventors:
Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
Abstract: A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility.
Type:
Grant
Filed:
December 22, 2009
Date of Patent:
May 21, 2019
Assignee:
XOMA (US) LLC
Inventors:
Patrick J. Scannon, Frank Bernard, Robert S. Tenerowicz, Alfred C. Dadson, Jr.
Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
April 9, 2019
Assignee:
XOMA (US) LLC
Inventors:
Paul Rubin, Toshihiko Takeuchi, Hassan Issafras, Kiranjit Ahluwalia, John Corbin, Ira Goldfine, Kirk Johnson, Ou Li, Daniel Bedinger
Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Type:
Grant
Filed:
April 3, 2016
Date of Patent:
January 1, 2019
Assignees:
XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Abstract: A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
October 23, 2018
Assignee:
XOMA (US) LLC
Inventors:
Patrick J. Scannon, Frank Bernard, Alfred C. Dadson, Jr., Robert S. Tenerowicz
Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
March 27, 2018
Assignees:
NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
Inventors:
Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz